Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 156Lung Neoplasms 57Uterine Cervical Neoplasms 53Squamous Cell Carcinoma of Head and Neck 52Nasopharyngeal Carcinoma 51Head and Neck Neoplasms 47Stomach Neoplasms 37Parkinson Disease 4, Autosomal Dominant Lewy Body 35Esophageal Neoplasms 31Urinary Bladder Neoplasms 26Small Cell Lung Carcinoma 21Esophageal Squamous Cell Carcinoma 21Ovarian Neoplasms 19Carcinoma 14Neoplasm Metastasis 13Cholangiocarcinoma 13Recurrence 11Neuroblastoma 11Nasopharyngeal Neoplasms 11Carcinoma, Ovarian Epithelial 11Biliary Tract Neoplasms 11Adenocarcinoma Of Esophagus 11Neoplasms 10Gallbladder Neoplasms 10Carcinoma, Transitional Cell 10Testicular Neoplasms 9Adenocarcinoma of Lung 9Teratoma 8Oropharyngeal Neoplasms 8Endometrial Neoplasms 8

Interventions

taxane 1liposomal doxorubicin 1Sorafenib 1Paclitaxel 1Docetaxel 1Cisplatin 1Biosimilar Pharmaceuticals 1Bevacizumab 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Vaccinia × Cisplatin × Clear all
NCT05281471 2026-03-18

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Genelux Corporation

Phase 3 Recruiting
186 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Vaccinia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡